Charts

LOS ANGELES, March 23, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) today announced that NXC-201 treatment continues to demonstrate 100% complete hematologic responses and 100% organ response rate – cardiac, renal, liver response – in a total of 8 AL amyloidosis patients (an additional 2 patients maintaining 100% complete response). Additionally, Nexcella announced new positive safety data in relapsed/refracto

LOS ANGELES, March 10, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases, today confirms that neither ImmixBio, nor any of its subsidiaries, have any exposure to Silicon Valley Bank (“SVB”) or Silvergate Bank. About Immix Biopharma, Inc.Immix Biopharma, Inc. (ImmixBio™) (Nasdaq: IMMX) is a clinical-stage biopharmaceutic

LOS ANGELES, March 06, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases, and its subsidiary Nexcella, Inc. (“Nexcella”), a biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today announced that Ilya Rachman, M.D., Ph.D., ImmixBio Chief Executi

Robust enrollment of up to 5 patients per month continues in ongoing Phase 1b/2a next-generation CAR-T NXC-201 clinical trial in relapsed/refractory multiple myeloma and relapsed/refractory AL amyloidosis Nexcella on track to present 50-patient cohort multiple myeloma data later this year at a premier scientific forum Los Angeles, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc. (“Nexcella”, “Company”), a biopharmaceutical company engaged in the discovery and development of novel cell therapies

Gainers TransMedics Group (NASDAQ:TMDX) stock moved upwards by 16.4% to $75.1 during Thursday's pre-market session. The market value of ...

Gainers TransMedics Group (NASDAQ:TMDX) stock moved upwards by 10.2% to $71.15 during Wednesday's after-market session. The market ...

Upgrades Maxim Group upgraded the previous rating for TOP Ships Inc (NASDAQ:TOPS) from Hold to Buy. NoneThe stock has a 52-week-high of ...

Gainers Windtree Therapeutics (NASDAQ:WINT) stock increased by 28.8% to $0.22 during Wednesday's pre-market session. The market value ...

Nexcella, Inc. initiates process of bringing NXC-201 to the United States by entering into an agreement with a well-known GMP cell therapy manufacturer that will supply Phase 1b/2 NXC-201 clinical trial materialNXC-201 is in development for the treatment of patients with relapsed or refractory multiple myeloma and light chain (AL) amyloidosis Nexcella believes recently reported Phase 1b data from the ongoing Phase 1b/2 clinical trial supports investigating NXC-201 as the first potential outpatie

The poster presents data for 42 patients with relapsed or refractory multiple myeloma who were treated with NXC-201 (formerly HBI0101), of which 29 received the therapeutic dose of 800 million CAR+T cells as of the data cutoff of October 23, 202290% overall response rate (ORR) was observed in 29 multiple myeloma patients receiving the therapeutic dose of NXC-20117 of 29 (59%) of patients receiving the therapeutic dose reached complete response (CR) or stringent complete response (sCR)Cytokine re

Gainers SenesTech (NASDAQ:SNES) shares moved upwards by 11.1% to $4.11 during Tuesday's after-market session. SenesTech's trading ...

IMX-110 + Beigene/Novartis anti-PD-1 Tislelizumab combination designed to enhance response to solid tumors by turning immunologically “cold” tumors “hot”Initial data anticipated in 1H 2023 LOS ANGELES, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, today announced dosing of the first 2 patients in its IMX-

Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the ...

In January 2023, the 17th new patient was dosed with IMX-110 to datePositive safety data enabled continued dosing of previously enrolled patients Patients undergo CT scans every 8 weeks after dosing to assess tumor response to IMX-110; clinical data expected to be released on a rolling basis beginning in Q1 2023 LOS ANGELES, Jan. 13, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeu

Gainers Spruce Biosciences (NASDAQ:SPRB) stock rose 80.0% to $2.25 during Friday's pre-market session. The market value of their ...

NXC-201 treatment continues to demonstrate 100% complete response rate in 6 relapsed/refractory AL amyloidosis patients to-dateClinical data published December 2022 in Clinical Cancer Research demonstrated 100% complete response rate; 100% organ response rate; Duration of Response Not Yet Reached at a median follow-up of 5.2 months, resulting in a mean 65% reduction (2,656pg/mL) in NT-proBNP from baseline; no grade 4 Cytokine Release Syndrome (CRS); no ICANS neurotoxicity was observed; a 2-stage

Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will be presented in Rotterdam, Netherlands February 9-11, 2023LOS ANGELES, CA, Dec. 28, 2022 (GLOBE NEWSWIRE) -- Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) today announced that updated NXC-201 clinical data has been selected to be presented at the upcoming European Society for Blood and Marrow Transplantation and European Hematology

Gainers Cue Health (NASDAQ:HLTH) shares rose 13.3% to $2.73 during Thursday's after-market session. The company's market cap stands at ...

16th patient dosed with IMX-110 to dateThis is the second patient dosed with IMX-110 in December 2022Patients undergo CT scans every 8 weeks after dosing to assess tumor response to IMX-110; clinical data expected to be released on a rolling basis beginning in Q1 2023 LOS ANGELES, CA, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)TM targeting oncology and immu

Tislelizumab supplied by BeiGene as part of ImmixBio’s Clinical Trial and Supply Agreement with BeiGene to Evaluate Combination of IMX-110 and Tislelizumab in Solid TumorsIMX-110 + Tislelizumab clinical trial data expected to be released on a rolling basis beginning in Q1 2023; once dosing begins, patients undergo CT scans every 8 weeks to assess tumor response to IMX-110 + Tislelizumab LOS ANGELES, CA, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”

U.S. stocks turned lower toward the end of trading, after the Federal Reserve announced its policy decision. The Dow traded down ...

Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares rose 153% to $0.3325 after gaining 14% on Tuesday. Crown ...

U.S. stocks traded higher midway through trading, with the Dow Jones gaining over 100 points on Wednesday The Dow traded up 0.42% to ...

Immix Biopharma Inc(NASDAQ: IMMX) announced it has in-licensed BCMA-targeted next-generation CAR-T therapy NXC-201 (formerly ...

Gainers Vallon Pharmaceuticals (NASDAQ:VLON) stock increased by 137.8% to $0.6 during Wednesday's regular session. Trading volume for ...

Multiple Myeloma - 85% overall response rate (71% CR/sCR) for NXC-201 at therapeutic dose in an ongoing Phase 1b study in 20 relapsed/refractory patients as of June 27, 2022 data cutoff (Haematologica https://doi.org/10.3324/haematol.2022.281628)AL Amyloidosis - 100% complete responses, 100% organ response rate for NXC-201 in 4 relapsed/refractory patients (Clinical Cancer Research https://doi.org/10.1158/1078-0432.CCR-22-0637)Potential first and only out-patient CAR-T: Low-grade CRS duration of

In December 2022, the 15th patient was dosed with IMX-110IMX-110 clinical trial data expected to be released on a rolling basis beginning in Q1 2023; once dosing begins, patients undergo CT scans every 8 weeks to assess tumor response to IMX-110IMX-110 monotherapy and IMX-110 combination clinical trial with Beigene/Novartis anti-PD-1 tislelizumab enabled by newly manufactured, scaled-up IMX-110 GMP batches LOS ANGELES, CA, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

LOS ANGELES, CA, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, today announced that it has completed release testing and shipped Good Manufacturing Practice (“GMP”) process manufactured batches of IMX-110 for clinical trial patient dosing. IMX-110 was produced using our proprietary, scaled-up manufacturin

Immix Biopharma Receives Institutional Review Board Approval to Enroll Pediatric Patients in Upcoming IMX-110 Clinical Trial, Key Requirement for U.S. Food and Drug Administration Approval of Rare Pediatric Disease Priority Review Voucher Immix Biopharma, Inc. (NASDAQ:IMMX) Enrolling pediatric patients in a clinical trial is a key requirement for FDA approval of a Priority Review Voucher (“PRV”)While their future value is uncertain, PRVs are transferable to other companies and have historically

OnThursday, 111 stocks hit new 52-week lows. Interesting Facts About Today's 52-Week Lows: Alphabet ...

On Wednesday, 53 companies reached new 52-week lows. Intriguing Points From Today's 52-Week Lows: Canon ...

On Tuesday, 120 companies set new 52-week lows. Areas of Significance In Today's 52-Week Lows: The largest ...

Immix Biopharma to Present Milestones Achieved to Enable Kick-Off of 2 IMX-110 Clinical Trials at the 2022 ThinkEquity Conference on October 26 Immix Biopharma, Inc. (NASDAQ:IMMX) A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/fe1f9d2e-f230-494b-9bb9-6b910a14f2aa LOS ANGELES, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specifi

Immix Biopharma, Inc. (NASDAQ:IMMX) ImmixBio Approves 4 Additional Clinical Trial Sites for IMX-110 Clinical Trials, Complementing Existing Soft Tissue Sarcoma Lead Site California Soft Tissue Sarcoma Site to lead expanded clinical site consortiumHistorically, high-enrolling lead site has enrolled 2-3 patients per monthClinical trial data expected to be released on a rolling basis beginning in Q1 2023; once dosing begins, patients undergo CT scans every 8 weeks to assess tumor response to IMX-11

New Equities that Broke Through 52-Week Lows Friday Morning During Friday's morning session, 121 stocks hit new 52-week ...

Gainers Homology Medicines (NASDAQ:FIXX) stock increased by 10.4% to $3.19 during Monday's after-market session. The ...

Gainers Apellis Pharmaceuticals (NASDAQ:APLS) shares rose 24.6% to $55.76 during Tuesday's pre-market session. The ...

Gainers Kiromic BioPharma, Inc. (NASDAQ: KRBP) gained 70% to $0.4900 after the company entered a sponsored research agreement ...

Gainers NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) shares gained 47.5% to settle at $0.8436 on Thursday. Based on the review of ...

Investors are attempting to brush off comments from Federal Reserve Vice President Lael Brainard, which reignited rate hike concerns.

Gainers Repare Therapeutics Inc. (NASDAQ: RPTX) jumped 38.1% to $12.08 after the company announced it has entered into a worldwide ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investors! It's time to start another day of trading with the biggest pre-market stock movers for Thursday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. Get in Now on Tiny $3 ‘Forever Battery’ Stock Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

Gainers Immix Biopharma, Inc. (NASDAQ: IMMX) rose 42.2% to $2.63 in pre-market trading after declining around 14% on Wednesday. ...

Gainers TherapeuticsMD, Inc. (NASDAQ: TXMD) shares climbed 364% to close at $9.93 on Tuesday after the company announced it has ...

Gainers TherapeuticsMD (NASDAQ:TXMD) stock rose 360.5% to $9.86 during Tuesday's regular session. As of 13:30 EST, ...

Gainers TherapeuticsMD, Inc. (NASDAQ: TXMD) shares jumped 360.8% to $9.86 after the company announced it has entered into a ...

Gainers Creatd, Inc. (NASDAQ: CRTD) shares jumped 58.5% to close at $1.28 on Thursday. Creatd’s board approved a rights ...

Gainers Healthcare Triangle, Inc. (NASDAQ: HCTI) shares gained 46.6% to $0.9824. Healthcare Triangle recently posted a ...

Gainers GeoVax Labs, Inc. (NASDAQ: GOVX) shares surged 90.2% to settle at $1.39 on Friday. GeoVax Labs, last month, said its Q1 ...

Gainers Immix Biopharma (NASDAQ:IMMX) shares increased by 52.1% to $2.48 during Friday's regular session. The ...

Immix Biopharma Inc(NASDAQ: IMMX) announcedpositive interim datafrom an animal study in Soft Tissue Sarcoma ...

Gainers NeuroMetrix, Inc. (NASDAQ: NURO) shares jumped 76.3% to close at $5.50 on Thursday after the company announced the FDA ...

Gainers Athenex (NASDAQ:ATNX) shares increased by 30.5% to $0.62 during Monday's pre-market session. The market ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Welcome back and get ready for another busy week of trading as we start it off with the biggest pre-market stock movers for Monday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. Get in Now on Tiny $3 ‘Forever Battery’ Stock Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

Gainers AgriFORCE Growing Systems Ltd. (NASDAQ: AGRI) rose 25.2% to $2.09 in pre-market trading after gaining around 10% on ...

Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM) shares surged 148.2% to close at $5.61 on Tuesday after the company announced ...

Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM) shares jumped 139% to $5.40 after the company announced that two of its designed ...

Gainers Trevi Therapeutics (NASDAQ:TRVI) stock moved upwards by 11.9% to $1.41 during Friday's after-market session. The market value ...